Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Triple Negative Breast Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Kenny-Caffey syndrome, Type 1 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Recurrence × fluzoparib × Clear all
NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡